https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Johnson and Johnson and Merck are healthcare giants with dependable returns that weather economic do

Stephane Bancel, CEO of Moderna , was at a Lebanese restaurant celebrating a friend's birthday late

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth

MRK hits a 52-week high as positive melanoma data, pipeline progress, new launches and M&A bolster i

VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five

Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target co

Beverly Hills Private Wealth LLC cut its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 59.7%

BlackRock Inc. increased its position in Merck and Co., Inc. (NYSE: MRK) by 0.5% in the second quart

Johnson credits Trump and Republicans for record low drug prices, stating Americans are seeing lower

The setup around Merck (NYSE:MRK | MRK Price Prediction) shares heading into September is unusual fo

Two unvaccinated Pennsylvania residents died of measles, the state’s first deaths in 35 years, as tr

These healthcare leaders are unlikely to suspend their dividend programs.

The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA tec

Wolfe Research analyst Alexandria Hammond maintains Merck & Co (NYSE:MRK) with a Outperform a

Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multib

On CNBC's Squawk on the Street Monday morning, Jim Cramer said the tape has soured on the trade that

Shares of Moderna are trading higher Tuesday morning, as Wall Street analysts upgrade their ratings

Argus Research analyst Jasper Hellweg maintains Merck & Co (NYSE:MRK) with a Buy and raises t

Court rejects Merck's lawsuit against Medicare drug price negotiations. Penalties for noncomplia

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi

Bank of New York Mellon Corp lowered its stake in Merck and Co., Inc. (NYSE: MRK) by 2.0% in the und

Bellars Harris Wealth Management LLC bought a new position in shares of Merck and Co., Inc. (NYSE: M

Chase Investment Counsel Corp grew its position in Merck and Co., Inc. (NYSE: MRK) by 57.7% during t

CORDA Investment Management LLC. lessened its stake in shares of Merck and Co., Inc. (NYSE: MRK) by

Global Retirement Partners LLC bought a new position in shares of Merck and Co., Inc. (NYSE: MRK) du

Focus Partners Advisor Solutions LLC trimmed its position in Merck and Co., Inc. (NYSE: MRK) by 11.9

ABN AMRO Bank N.V. reduced its position in Merck and Co., Inc. (NYSE: MRK) by 7.6% during the undefi

Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 7% to $135.22 in Monday morning trading,

Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “qui

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo

Retail investors talked up 5 hot stocks during the week (Aug. 17 to Aug. 21) on X and Reddit's r

Goldman Sachs analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Buy and raises the

Moderna's Phase 3 cancer vaccine breakthrough could mark a turning point as the biotech company

Moderna closed up 176.97% on first-ever Phase 3 win for an mRNA cancer vaccine, then gave back as mu

BMO Capital analyst Evan David Seigerman maintains Merck & Co (NYSE:MRK) with a Outperform an

Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amta

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine,

Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/down

William Blair upgraded Moderna to Outperform, citing higher intismeran approval odds and a multibill

RBC Capital analyst Trung Huynh downgrades Merck & Co (NYSE:MRK) from Outperform to Sector Pe

Pharma Bro Martin Shkreli admits shorting Moderna at $80 just weeks before a landmark cancer vaccine

Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst r

Editor’s note: The ETFs data was updated and economic data was added U.S. stock futures were lowe

Tempus AI (TEM) trades higher after positive Phase 3 mRNA cancer trial results spotlight its $1.5B a

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software p

Morgan Stanley analyst Terence Flynn upgrades Merck & Co (NYSE:MRK) from Equal-Weight to Over